Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471366 | 0.86 | CES2 (0.54) | AKT1CES2CES1ALDH5A1ABAT | |
| SCHEMBL28959137 | 0.77 | AKT1 (0.41) | AKT1ALDH5A1ABATMEN1KMT2A | |
| SCHEMBL30827198 | 0.77 | AKT1 (0.41) | AKT1ALDH5A1ABATMEN1KMT2A | |
| SCHEMBL560207 | 0.75 | HCAR1 (0.59) | CES2CES1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29759213 | 0.75 | HCAR1 (0.59) | CES2CES1MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5226036 | 0.74 | HCAR1 (0.57) | CES2CES1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31327392 | 0.74 | CES2 (0.44) | CES2CES1ALDH1A1EGFRALOX15 | |
| SCHEMBL1764905 | 0.74 | CES2 (0.44) | CES2CES1ALDH1A1HPGDHCAR1 | |
| SCHEMBL5225361 | 0.74 | CES2 (0.44) | CES2CES1ALDH1A1EGFRALOX15 | |
| SCHEMBL31222695 | 0.74 | PARP1 (0.50) | CES2CES1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| US-20240262815-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC (KR) | 2024-08-08 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | US | disclosed |
| EP-4342895-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-03-27 | — | — | EP | disclosed |
| EP-4335847-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Voronoi Inc. (KR) | 2024-03-13 | — | — | EP | disclosed |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| CN-117255792-A | Heteroaryl derivatives, process for preparing the same and pharmaceutical compositions comprising the same as active ingredient | 沃若诺伊公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2022245085-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2022-11-24 | — | — | WO | disclosed |
| WO-2022234965-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022234965-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | AKT1 40/4885CES2 2857/4885CES1 3727/4885 |
| US-20240262815-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, ERBB4, ERBB3 | AKT1 392/4885CES2 4003/4885CES1 3862/4885 |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | AKT1 40/4885CES2 2857/4885CES1 3727/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | AKT1 447/4885CES2 1116/4885CES1 706/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | AKT1 139/4885CES2 1186/4885CES1 807/4885 |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | AKT1 40/4885CES2 2857/4885CES1 3727/4885 |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | AKT1 40/4885CES2 2857/4885CES1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.